LeRoith D - Search Results

1

The insulin-like growth factor system and cancer.

LeRoith D, Roberts CT Jr. LeRoith D, et al. Cancer Lett. 2003 Jun 10;195(2):127-37. doi: 10.1016/s0304-3835(03)00159-9. Cancer Lett. 2003. PMID: 12767520 Review.

2

Non-islet cell hypoglycemia.

LeRoith D. LeRoith D. Ann Endocrinol (Paris). 2004 Feb;65(1):99-103. doi: 10.1016/s0003-4266(04)95641-7. Ann Endocrinol (Paris). 2004. PMID: 15122103 Review.

3

Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol.

Kleinman D, Karas M, Roberts CT Jr, LeRoith D, Phillip M, Segev Y, Levy J, Sharoni Y. Kleinman D, et al. Among authors: leroith d. Endocrinology. 1995 Jun;136(6):2531-7. doi: 10.1210/endo.136.6.7750475. Endocrinology. 1995. PMID: 7750475

4

Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess.

Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B. Barbour LA, et al. Among authors: leroith d. J Biol Chem. 2005 Nov 11;280(45):37489-94. doi: 10.1074/jbc.M506967200. Epub 2005 Sep 8. J Biol Chem. 2005. PMID: 16166093

5

14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation.

Zhang Y, Karas M, Zhao H, Yakar S, LeRoith D. Zhang Y, et al. Among authors: leroith d. J Biol Chem. 2004 Aug 13;279(33):34353-60. doi: 10.1074/jbc.M401300200. Epub 2004 Jun 8. J Biol Chem. 2004. PMID: 15187095

6

Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.

Mosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, Chen C. Mosa R, et al. Among authors: leroith d. Endocrinology. 2017 Oct 1;158(10):3174-3187. doi: 10.1210/en.2017-00168. Endocrinology. 2017. PMID: 28977588 Free PMC article.

7

Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.

Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D. Yakar S, et al. Among authors: leroith d. J Clin Invest. 2004 Jan;113(1):96-105. doi: 10.1172/JCI17763. J Clin Invest. 2004. PMID: 14702113 Free PMC article.

8

Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.

Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S, LeRoith D. Pennisi P, et al. Among authors: leroith d. Endocrinology. 2006 Jun;147(6):2619-30. doi: 10.1210/en.2005-1556. Epub 2006 Mar 2. Endocrinology. 2006. PMID: 16513827

9

Mouse models created to study the pathophysiology of Type 2 diabetes.

LeRoith D, Gavrilova O. LeRoith D, et al. Int J Biochem Cell Biol. 2006;38(5-6):904-12. doi: 10.1016/j.biocel.2005.01.019. Epub 2005 Aug 2. Int J Biochem Cell Biol. 2006. PMID: 16103004 Review.

10

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D. Kim H, et al. Among authors: leroith d. Diabetes. 2003 Jul;52(7):1770-8. doi: 10.2337/diabetes.52.7.1770. Diabetes. 2003. PMID: 12829645

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results